cccDNA
HBx公司
乙型肝炎表面抗原
环状DNA
慢性肝炎
抗原
医学
免疫系统
乙型肝炎
免疫学
病毒学
乙型肝炎病毒
生物
病毒
基因组
基因
生物化学
作者
Lung‐Yi Mak,Ka‐Shing Cheung,James Fung,Wai‐Kay Seto,Man‐Fung Yuen
标识
DOI:10.1016/j.molmed.2022.06.002
摘要
Functional cure, as defined by seroclearance of hepatitis B surface antigen (HBsAg), is the desired treatment endpoint for chronic hepatitis B (CHB) infection, yet is rarely achieved with the currently approved therapy. Novel treatments currently in the clinical phase of development act by inhibiting viral replication/antigen reduction and/or by restoring host immune control. Although some agents are effective in reducing the viral antigen load, a greater magnitude of suppression is required to achieve functional cure. Compounds that target the covalently closed circular DNA (cccDNA) pool, hepatitis B X (HBx) protein inhibition, and mRNA destabilization are also in the preclinical phase of development. Challenges which remain include the clinical implications, immunological perturbations, and safety of these novel compounds to be used in the real-life setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI